Our data lay the basis for exploring the implication of NO–sGC–PRKG signaling in other forms of TAAD and determining the potential of sGC or PKRG inhibition in the treatment of patients with MFS or other forms of TAAD. This evidence concerns the gene SGCB and Marfan syndrome.